MiMedx Group, Inc. (MDXG) Income Statement Analysis

See more : Centrais Elétricas Brasileiras S.A. – Eletrobrás (ELET5.SA) Income Statement Analysis – Financial Results

Complete financial analysis of MiMedx Group, Inc. (MDXG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MiMedx Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

PT Gunung Raja Paksi Tbk (GGRP.JK) Income Statement Analysis – Financial Results
Eucrates Biomedical Acquisition Corp. (EUCRW) Income Statement Analysis – Financial Results
Kore Potash plc (KP2.L) Income Statement Analysis – Financial Results
Sunko Ink Co., Ltd. (1721.TW) Income Statement Analysis – Financial Results
Pure Hydrogen Corporation Limited (PH2.AX) Income Statement Analysis – Financial Results

MiMedx Group, Inc. (MDXG)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.mimedx.com

About MiMedx Group, Inc.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006
Revenue	321.48M	267.84M	258.62M	248.23M	299.26M	359.11M	321.14M	245.02M	187.30M	118.22M	59.18M	27.05M	7.76M	788.87K	0.00	0.00	0.00	0.00
Cost of Revenue	54.63M	48.32M	43.28M	39.33M	43.08M	36.39M	35.22M	32.41M	20.20M	12.67M	9.33M	5.19M	3.15M	1.72M	0.00	0.00	0.00	0.00
Gross Profit	266.84M	219.53M	215.33M	208.90M	256.17M	322.73M	285.92M	212.61M	167.09M	105.56M	49.85M	21.87M	4.61M	-931.19K	0.00	0.00	0.00	0.00
Gross Profit Ratio	83.01%	81.96%	83.26%	84.16%	85.60%	89.87%	89.03%	86.77%	89.21%	89.29%	84.24%	80.82%	59.35%	-118.04%	0.00%	0.00%	0.00%	0.00%
Research & Development	12.67M	22.83M	17.34M	11.72M	11.14M	15.77M	17.90M	12.04M	8.41M	7.05M	4.84M	2.88M	2.60M	2.75M	4.02M	2.01M	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	7.96M	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	211.12M	208.79M	198.36M	181.02M	198.21M	258.53M	220.12M	180.00M	133.38M	90.48M	46.23M	20.97M	11.76M	6.85M	7.96M	8.66M	36.81K	16.15K
Other Expenses	5.94M	12.88M	4.61M	60.54M	67.54M	527.00K	-87.00K	2.13M	933.00K	928.00K	1.05M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	229.73M	244.50M	220.31M	253.28M	276.89M	326.65M	239.70M	194.16M	142.73M	98.46M	52.12M	23.86M	14.37M	9.60M	11.98M	10.67M	36.81K	16.15K
Cost & Expenses	284.36M	292.81M	263.60M	292.61M	319.97M	363.04M	274.92M	226.57M	162.93M	111.12M	61.45M	29.04M	17.52M	11.32M	11.98M	10.67M	36.81K	16.15K
Interest Income	0.00	5.02M	4.98M	7.94M	4.71M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	59.55K	519.71K	0.00	0.00
Interest Expense	6.46M	5.02M	4.98M	7.94M	4.71M	0.00	0.00	339.00K	86.00K	48.00K	1.37M	2.31M	432.97K	599.65K	0.00	0.00	2.05K	590.00
Depreciation & Amortization	3.43M	4.05M	6.17M	7.84M	8.53M	6.92M	5.77M	5.46M	2.73M	2.13M	1.69M	1.85M	1.78M	1.11M	1.09M	500.26K	0.00	0.00
EBITDA	40.52M	-10.69M	-1.89M	-45.76M	-12.35M	2.99M	53.04M	23.91M	27.10M	9.23M	-947.35K	-3.51M	-7.98M	-9.71M	-10.89M	-10.83M	-36.81K	-16.15K
EBITDA Ratio	12.60%	-7.81%	0.07%	-15.11%	-4.24%	0.83%	16.51%	9.76%	14.47%	7.80%	-0.98%	-7.36%	-102.81%	-1,230.60%	0.00%	0.00%	0.00%	0.00%
Operating Income	37.12M	-24.97M	-5.01M	-44.37M	-20.71M	-3.92M	46.22M	18.45M	24.36M	7.10M	-2.64M	-5.36M	-9.76M	-10.53M	-11.98M	-17.85M	-36.81K	-16.15K
Operating Income Ratio	11.55%	-9.32%	-1.94%	-17.87%	-6.92%	-1.09%	14.39%	7.53%	13.01%	6.01%	-4.46%	-19.80%	-125.78%	-1,335.15%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	-6.48M	-5.02M	-2.99M	-16.15M	-4.43M	527.00K	-1.14M	-339.00K	-86.00K	-48.00K	-1.37M	-2.31M	-432.97K	-887.10K	59.55K	-5.39M	-2.05K	-634.63K
Income Before Tax	30.63M	-29.99M	-10.04M	-61.54M	-25.59M	-3.40M	45.09M	18.11M	24.28M	7.05M	-4.01M	-7.66M	-10.19M	-11.42M	-11.92M	-17.37M	-38.86K	-16.74K
Income Before Tax Ratio	9.53%	-11.20%	-3.88%	-24.79%	-8.55%	-0.95%	14.04%	7.39%	12.96%	5.96%	-6.78%	-28.32%	-131.36%	-1,447.60%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-36.81M	206.00K	247.00K	-12.26M	-5.00K	26.58M	-19.64M	6.13M	-5.17M	832.00K	99.61K	2.31M	432.97K	887.10K	-59.55K	-477.93K	0.00	0.00
Net Income	67.44M	-30.20M	-10.29M	-49.28M	-25.58M	-29.98M	64.73M	11.97M	29.45M	6.22M	-4.11M	-7.66M	-10.19M	-11.42M	-11.92M	-17.37M	-38.86K	-16.74K
Net Income Ratio	20.98%	-11.27%	-3.98%	-19.85%	-8.55%	-8.35%	20.16%	4.89%	15.72%	5.26%	-6.95%	-28.32%	-131.36%	-1,447.60%	0.00%	0.00%	0.00%	0.00%
EPS	0.48	-0.27	-0.09	-0.46	-0.24	-0.28	0.61	0.00	0.28	0.06	-0.04	-0.09	-0.14	-0.19	-0.32	-3.00	-0.01	0.00
EPS Diluted	0.38	-0.27	-0.09	-0.46	-0.24	-0.28	0.56	0.00	0.26	0.05	-0.04	-0.09	-0.14	-0.19	-0.32	-3.00	-0.01	0.00
Weighted Avg Shares Out	116.50M	112.91M	110.35M	108.26M	106.95M	105.60M	106.12M	105.93M	105.93M	105.79M	96.29M	81.65M	72.45M	59.14M	37.74M	5.79M	7.40M	5.68M
Weighted Avg Shares Out (Dil)	145.96M	112.91M	110.35M	108.26M	106.95M	105.60M	116.11M	112.65M	113.63M	113.30M	96.29M	81.65M	72.45M	59.14M	37.74M	5.79M	7.40M	5.68M

MiMedx Announces First Quarter 2021 Financial and Operating Results

April 28, 2021globenewswire.com

First Quarter Net Sales of $60.0 Million

MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs

April 28, 2021globenewswire.com

Accomplished Regulatory Leader Joins MiMedx Management Team

MiMedx Announces Last Patients Last Visits in Three Late-Stage Musculoskeletal Trials with Proprietary Tissue Technology

April 19, 2021globenewswire.com

Advances Potential for Use of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) as a Safe and Effective Treatment Option

MiMedx Confirms Receipt of Director Nominations from Prescience Point Capital Management

April 16, 2021globenewswire.com

No Shareholder Action Required at This Time

Prescience Point Capital Management to Nominate Four Highly Qualified Director Candidates to MiMedx Board at 2021 Annual Meeting

April 16, 2021prnewswire.com

BATON ROUGE, La., April 16, 2021 /PRNewswire/ -- Prescience Point Capital Management, together with its affiliates ("Prescience Point"), a research-focused, catalyst-driven investment firm, announced today the nomination of four highly qualified director candidates to the Board of Directors (the "Board") of...

MDXG Stock Price Increased Over 5% Pre-Market: Why It Happened

March 30, 2021pulse2.com

The stock price of MiMedx Group, Inc. (Nasdaq: MDXG) has increased by over 5% pre-market. This is why it happened.

MiMedx Awarded Amniotic Tissue Supplier Agreement with Premier® Inc.'s SURPASS™ Purchasing Program

March 30, 2021globenewswire.com

MARIETTA, Ga., March 30, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced that the Company has been awarded a Group...